Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TOWA Pharmaceutical CoTWAPF 81 3-Year EBITDA Growth Rate is 15.80% as of Mar. 2026, which is 3% above its 10-year median of 15.40. GuruFocus rates TWAPF with a GF Score™ of 81/100 and a GF Value™ of $23.16 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 809 Drug Manufacturers companies, TOWA Pharmaceutical Co ranks better than 61.68% on this metric.
During the past 12 months, TOWA Pharmaceutical Co's average EBITDA Per Share Growth Rate was -20.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 15.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of TOWA Pharmaceutical Co was 35.00% per year. The lowest was -6.20% per year. And the median was 15.40% per year.
TOWA Pharmaceutical Co (OTCPK:TWAPF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
TOWA Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms
TWAPF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TOWA Pharmaceutical Co 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where TOWA Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.
TOWA Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 15.80% mean?
TOWA Pharmaceutical Co (TWAPF) has a 3-Year EBITDA Growth Rate of 15.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for TOWA Pharmaceutical Co and its competitors. This is near median its historical median of 15.40. According to the industry distribution chart, TOWA Pharmaceutical Co ranks #310 out of 809 companies in the Drug Manufacturers industry, placing it in the top 38.3%.
Is TOWA Pharmaceutical Co's 3-Year EBITDA Growth Rate too high?
TOWA Pharmaceutical Co's current 3-Year EBITDA Growth Rate of 15.80% is near median its 10-year median of 15.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. TOWA Pharmaceutical Co's value of 15.80% is 77.5% above this industry median. Based on the distribution chart, TOWA Pharmaceutical Co ranks #310 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TOWA Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TOWA Pharmaceutical Co ranks #310 out of 809 companies for 3-Year EBITDA Growth Rate. This puts TOWA Pharmaceutical Co in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. TOWA Pharmaceutical Co's value of 15.80% is 77.5% above this benchmark. While the company's 10-year median is 15.40 vs. the industry median of 8.90, TOWA Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TOWA Pharmaceutical Co's current 3-Year EBITDA Growth Rate of 15.80% is 77.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for TOWA Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TOWA Pharmaceutical Co's current 3-Year EBITDA Growth Rate is 15.80%, which is near median its own 10-year median of 15.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (TWAPF) is currently considered Modestly Overvalued. The stock's GF Value™ is $23.16, compared to a current price of $25.98 — trading 12.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 15.80%, which is near median its 10-year median of 15.40 and 77.5% above the Drug Manufacturers industry median of 8.90. TOWA Pharmaceutical Co's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For TOWA Pharmaceutical Co (TWAPF), the current 3-Year EBITDA Growth Rate is 15.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TOWA Pharmaceutical Co (TWAPF) Overvalued in 2026?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued.
The current stock price of $25.98 is trading 12.2% above its estimated GF Value™ of $23.16.
GuruFocus considers TOWA Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TWAPF:
3-Year EBITDA Growth Rate: 15.80% (near median its 10-year median of 15.40)
GF Value™: $23.16 vs. price of $25.98 (12.2% above fair value)
Industry Position: 77.5% above the Drug Manufacturers median (#310 of 809)
No single metric tells the full story. See the TWAPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
81GF Score
Get the complete analysis for TWAPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TWAPF has been successfully added to your 
